WO2022255810A1 - 항노화 화장료 조성물 - Google Patents
항노화 화장료 조성물 Download PDFInfo
- Publication number
- WO2022255810A1 WO2022255810A1 PCT/KR2022/007823 KR2022007823W WO2022255810A1 WO 2022255810 A1 WO2022255810 A1 WO 2022255810A1 KR 2022007823 W KR2022007823 W KR 2022007823W WO 2022255810 A1 WO2022255810 A1 WO 2022255810A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound represented
- acceptable salt
- pharmaceutically acceptable
- skin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 239000002537 cosmetic Substances 0.000 title claims description 16
- 230000003712 anti-aging effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 86
- 230000037303 wrinkles Effects 0.000 claims abstract description 51
- 230000037394 skin elasticity Effects 0.000 claims abstract description 36
- 210000002469 basement membrane Anatomy 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 18
- 238000005728 strengthening Methods 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims description 69
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 abstract description 13
- 230000002500 effect on skin Effects 0.000 abstract description 6
- 210000003491 skin Anatomy 0.000 description 41
- -1 pack Substances 0.000 description 28
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 27
- 238000000034 method Methods 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 19
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 18
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 16
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 14
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 229940126864 fibroblast growth factor Drugs 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 235000005875 quercetin Nutrition 0.000 description 14
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 13
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 13
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 13
- 229960001285 quercetin Drugs 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 239000002674 ointment Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 9
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000008921 facial expression Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 101150095289 FGF7 gene Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000009982 effect on human Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000010512 hydrogenated peanut oil Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- BOJKULTULYSRAS-ACAGNQJTSA-N (3z)-4-hydroxy-3-[2-[6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethylidene]oxolan-2-one Chemical compound C=C1CCC2C(C)(CO)C(O)CCC2(C)C1C\C=C1\C(O)COC1=O BOJKULTULYSRAS-ACAGNQJTSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical class CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical group CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- CXQWRCVTCMQVQX-UHFFFAOYSA-N cis-dihydroquercetin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to a composition for strengthening the skin dermis layer by strengthening the skin basement membrane and improving skin elasticity or skin wrinkles.
- Collagen is a major matrix protein produced by fibroblasts of the skin and exists in the extracellular matrix. Collagen is known to play important functions related to the mechanical firmness of the skin, the resistance and cohesiveness of connective tissue, the support of cell adhesion, and the induction of cell division and differentiation (in the growth of organisms or wound healing). Such collagen is reduced by natural aging with increasing age or photoaging by ultraviolet irradiation, and the reduction process is promoted by the activity of collagenase enzyme that decomposes collagen. It is known that the decrease in collagen is closely related to the decrease in skin elasticity or the formation of wrinkles. Collagen is a fibrous protein found in mammals and constitutes bone, cartilage, basement membrane, and the like in the body.
- the skin basement membrane plays an important role in supporting and adhering epidermal cells, transporting nutrients, and controlling epidermal differentiation.
- the skin basement membrane is damaged due to aging, flattening, multiplexing, insulation, etc. of the basement membrane occur, resulting in wrinkles, and the possibility of external risk factors penetrating into the dermis increases, which can easily damage the skin. Therefore, in order to restore the damaged skin basement membrane or maintain it in a healthy state, its components must be properly maintained.
- fibroblast growth factor is one of the growth factors that regulate the proliferation, migration, differentiation and survival of various cells, and is composed of a group of proteins consisting of 23 types. FGF is produced in keratinocytes, fibroblasts, vascular endothelial cells, smooth muscle cells, chondrocytes and mast cells, etc., and exhibits the above-described functions by activating four types of fibroblast growth factor receptors (FGF receptors) expressed in various cells. In particular, it is known that FGF 2, FGF 7 and FGF 10 play important functions in skin regeneration (Non-Patent Document 1). FGF 7 and FGF 10 are involved in the re-epithelial process by promoting the proliferation of keratinocytes, and are also involved in the process of maintaining keratinocytes by neutralizing active oxygen.
- FGF 7 and FGF 10 are involved in the re-epithelial process by promoting the proliferation of keratinocytes, and are also involved in the process of maintaining keratinocytes by neutralizing
- the present inventors have endeavored to find a composition that exhibits skin elasticity or wrinkle improvement effect as an anti-aging effect by strengthening the skin basement membrane. It was confirmed that quercetin represented by Chemical Formula 3 exhibits an effect of improving skin elasticity or wrinkles, and in particular, a compound represented by Chemical Formula 1; And when the compound represented by Formula 2 and / or the compound represented by 3 are used together, it was confirmed that there is an excellent effect in strengthening the skin dermal layer, improving skin elasticity and reducing wrinkles, thereby completing the present invention.
- an object of the present invention is a compound represented by Formula 1 or a physiologically acceptable salt thereof; And to provide a cosmetic composition for improving skin elasticity or wrinkles comprising a compound represented by Formula 2 or a physiologically acceptable salt thereof and/or a compound represented by Formula 3 or a physiologically acceptable salt thereof as an active ingredient. .
- Another object of the present invention is a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; And providing a pharmaceutical composition for improving skin elasticity or wrinkles comprising a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof and/or a compound represented by Formula 3 or a pharmaceutically acceptable salt thereof as an active ingredient will be.
- the present invention is a compound represented by Formula 1 or a physiologically acceptable salt thereof; And it provides a cosmetic composition for improving skin elasticity or wrinkles comprising a compound represented by Formula 2 or a physiologically acceptable salt thereof and/or a compound represented by Formula 3 or a physiologically acceptable salt thereof as an active ingredient.
- the present invention is a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for improving skin elasticity or wrinkles comprising a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof and/or a compound represented by Formula 3 or a pharmaceutically acceptable salt thereof as an active ingredient. .
- the present invention relates to a compound represented by Formula 1 or a physiologically acceptable salt thereof; And treating the skin with a cosmetic composition comprising a compound represented by Formula 2 or a physiologically acceptable salt thereof and/or a compound represented by Formula 3 or a physiologically acceptable salt thereof as an active ingredient, A method for improving skin elasticity or wrinkles is provided.
- the present invention relates to a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; And administering a pharmaceutical composition comprising a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof and/or a compound represented by Formula 3 or a pharmaceutically acceptable salt thereof as an active ingredient to the skin.
- a method for improving elasticity or wrinkles is provided.
- the present invention relates to a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof for preparing a product for improving skin elasticity or wrinkles; and a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof and/or a compound represented by Formula 3 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compound represented by Chemical Formula 1 has a molecular formula of C 10 H 13 N 5 O 3 and a molecular weight of 251.12 g/mol, and includes Cordycepin, 3'-deoxyadenosine, 3'-deoxy-adenosine, 9-cordyceposidoadenine, 9-( 3-Deoxy-bD-erythro-pentofuranosyl)-9Hpurin-6-amine, 9-(3-Deoxy-bD-ribofuranosyl)adenine, etc.
- the present invention is not particularly limited to the method for obtaining the cordycepin, and it may be chemically synthesized by a method known in the art or a commercially available material may be used.
- the content of cordycepin may be 0.00001 to 10% by weight based on the total weight of the composition, for example, 0.00001 to 8% by weight, 0.00001 to 5% by weight, 0.00001 to 3% by weight, or 0.00001 to 0.00001% by weight. 2 wt%, 0.00001 to 1 wt%, or 0.00002 to 1 wt%.
- the compound represented by Formula 2 has a molecular formula of C 20 H 30 O5 and a molecular weight of 350.45 g/mol, and is composed of andrographolide, 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5 ,8a-dimethyl-2-methylene-1- napthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone.
- the present invention is not particularly limited to the method for obtaining the andrographolide, and it may be chemically synthesized by a method known in the art or a commercially available material may be used.
- the content of the andrographolide may be 0.00001 to 10% by weight based on the total weight of the composition, for example, 0.00001 to 8% by weight, 0.00001 to 5% by weight, 0.00001 to 3% by weight, 0.00001 to 2 wt%, 0.00001 to 1 wt%, or 0.00002 to 1 wt%.
- the compound represented by Chemical Formula 3 has a molecular formula of C 15 H 10 O 7 and a molecular weight of 302.236 g/mol, and is composed of quercetin, quercetin, 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-1 -benzopyran-4-one, 3,3′,4′,5,7-Pentahydroxyflavone, 5,7,3′,4′-flavon-3-ol are named.
- the present invention is not particularly limited to the method for obtaining the quercetin, and it may be chemically synthesized by a method known in the art or a commercially available material may be used.
- the content of the quercetin may be 0.00001 to 10% by weight based on the total weight of the composition, for example, 0.00001 to 8% by weight, 0.00001 to 5% by weight, 0.00001 to 3% by weight, 0.00001 to 2% by weight. weight percent, 0.00001 to 1 weight percent, or 0.00002 to 1 weight percent.
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof and the compound represented by Formula 2 or a pharmaceutically acceptable salt thereof have a weight ratio of 100: 1 to 1: 100, Or it may include a weight ratio of 50:1 to 1:50.
- the weight ratio of the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof and the compound represented by Formula 3 or a pharmaceutically acceptable salt thereof is 100:1 to 1:100, or 50 :1 to 1:50 by weight.
- the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof in the composition according to the present invention, the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; and 100:1 to 1:100 weight ratio of the total amount of the compound represented by Formula 2 or a pharmaceutically acceptable salt thereof and the compound represented by Formula 3 or a pharmaceutically acceptable salt thereof, or 50:1 to 1: 50 by weight.
- skin elasticity improving effect refers to preventing, suppressing or inhibiting the decrease in skin elasticity, or improving already reduced skin elasticity.
- wrinkle improvement effect refers to preventing, suppressing or inhibiting the formation of wrinkles on the skin, or alleviating wrinkles already formed.
- the mRNA expression of FGF 10 was promoted when human fibroblasts were treated with cordycepin, a compound represented by Formula 1, and andrographolide, a compound represented by Formula 2, in humans. It was confirmed that the mRNA expression of FGF 10 was promoted when fibroblasts were treated, and when quercetin, a compound represented by Chemical Formula 3, was treated with human fibroblasts, it was confirmed that the mRNA expression of FGF 10 was promoted. In addition, it was confirmed that when human fibroblasts were treated with andrographolide or quercetin together with cordycepin, the mRNA expression level of FGF 10 was increased more than cordycepin alone, andrographolide alone, and quercetin alone.
- FGF 10 is expressed in fibroblasts constituting the dermis, and is known to play a role in strengthening and maintaining a normal skin basement membrane.
- FGF 10 plays a role in maintaining skin integrity through signal transmission between the epidermis and dermis, and interacts with heparin sulfate, a major proteoglycan constituting the basement membrane, to promote epidermal cell growth, It is involved in division, attachment and migration.
- heparin sulfate a major proteoglycan constituting the basement membrane
- the composition of the present invention promotes the proliferation of fibroblasts in the skin basement membrane by expressing FGF 10, thereby strengthening the skin basement membrane, thereby exhibiting an effect of improving skin elasticity or wrinkles.
- the composition of the present invention may include a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; And a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof or a compound represented by Formula 3 or a pharmaceutically acceptable salt thereof may be included at the same time, and the composition may include a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
- the effect of improving skin elasticity or wrinkles is more excellent than a composition containing alone an acceptable salt, a compound represented by Formula 2, or a pharmaceutically acceptable salt thereof, or a compound represented by Formula 3, or a pharmaceutically acceptable salt thereof. can do.
- composition according to the present invention is a solution, external ointment, cream, foam, nutrient lotion, softening lotion, pack, softening water, emulsion, makeup base, essence, soap, detergent, bath additive, sunscreen cream, sun oil, suspension, emulsion, Pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays can be prepared in formulations selected from the group consisting of, preferably lotion, essence , It may be a lotion, cream, pack, gel, powder, foundation or cleanser, but is not limited thereto.
- the cosmetic composition may further include one or more cosmetically acceptable carriers formulated in general skin cosmetics, and as typical ingredients, for example, oil, water, surfactants, moisturizers, lower alcohols, and thickeners.
- one or more cosmetically acceptable carriers formulated in general skin cosmetics, and as typical ingredients, for example, oil, water, surfactants, moisturizers, lower alcohols, and thickeners.
- a chelating agent, a colorant, a preservative, a flavoring agent, etc. may be suitably formulated, but are not limited thereto.
- lactose When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as a carrier component, and especially in the case of a spray, chloro propellants such as fluorohydrocarbons, propane/butane or dimethyl ether.
- chloro propellants such as fluorohydrocarbons, propane/butane or dimethyl ether.
- a solvent, solubilizing agent, or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3 -There is butyl glycol oil, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
- the dosage form of the present invention is a suspension
- a liquid diluent such as water, ethanol or propylene glycol
- a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, a micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.
- the formulation of the present invention is a soap
- alkali metal salts of fatty acids fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars, etc.
- fatty acids fatty acid hemiester salts
- fatty acid protein hydrolyzates fatty acid protein hydrolyzates
- isethionates lanolin derivatives
- aliphatic alcohols aliphatic alcohols
- vegetable oils glycerol, sugars, etc.
- the present invention also relates to a compound represented by Formula 1 or a physiologically acceptable salt thereof; and treating the subject's skin with a cosmetic composition comprising a compound represented by Formula 2 or a physiologically acceptable salt thereof and/or a compound represented by Formula 3 or a physiologically acceptable salt thereof as an active ingredient. It provides a method for improving skin elasticity or wrinkles.
- the subject includes, without limitation, mammals including humans, livestock, mice, and the like.
- the present invention relates to a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof for preparing a product for improving skin elasticity or wrinkles; and a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof and/or a compound represented by Formula 3 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the pharmaceutical composition of the present invention may include the active ingredient alone, and may further include a pharmaceutically acceptable carrier, excipient, diluent, or auxiliary component depending on the formulation, method of use, and purpose of use.
- nutrients in addition to the above active ingredients, nutrients, vitamins, electrolytes, flavors, colorants, boosters, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, It may further contain glycerin, alcohol, a carbonating agent used in carbonated beverages, and the like.
- pharmaceutically acceptable means that it is physiologically acceptable and does not usually cause allergic reactions such as gastrointestinal disorders and dizziness or similar reactions when administered to animals, preferably humans.
- the pharmaceutically effective amount may be appropriately changed depending on the disease and its severity, the patient's age, weight, health condition, sex, administration route or treatment period.
- Examples of the pharmaceutically acceptable carrier, excipient or diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, propylhydroxybenzoate, talc, magnesium stearate and mineral oil , dextrin, calcium carbonate, dextrin, calcium carbonate, propylene glycol, liquid paraffin, and at least one selected from the group consisting of physiological saline, but is not limited thereto, and all conventional carriers, excipients, or diluents can be used.
- the formulation of the pharmaceutical composition may vary depending on the method of use, and is formulated using a method well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. It can be.
- examples of the formulation include ointments, creams, tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, aqueous solutions, non-aqueous solutions, suspensions, emulsions, and patches.
- excipients for example, conventional fillers, extenders, binders, disintegrants, surfactants, anti-agglomerating agents, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, sweeteners, aromatics or preservatives may be further included.
- solid preparations for oral administration include tablets (TABLETS), pills, soft or hard capsules (CAPSULES), pills (PILLS), powders (POWDERS) and granules (GRANULES), etc.
- these preparations include one or more Excipients, for example, may be prepared by mixing starch, calcium carbonate, sucrose or lactose, gelatin, and the like.
- lubricants such as magnesium stearate and talc may also be used.
- liquid preparations for oral administration include suspensions, internal solutions, emulsions, and syrups.
- various excipients for example, Humectants, sweetening agents, flavoring agents, preservatives, and the like may be included.
- compositions suitable for producing dusting powders, emulsions, suspensions, oils, sprays, ointments, grease ointments, cream pastes, gels, foams, or solutions, and transdermal therapeutic systems (TTS). ) are suitable carriers and/or excipients.
- the composition of the present invention may be a semi-solid dosage form, in particular an ointment (solution ointment, suspension ointment), cream, gel or paste.
- Mainly used in the oil phase are fatty alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol, fatty acids such as palmitic acid or stearic acid, liquid or solid paraffin or ozokerite, liquid to solid waxes such as such as isopropyl myristate, natural fats or some synthetic fats such as coconut fatty acid triglycerides, hydrogenated oils such as hydrogenated peanut or castor oil, or fatty acid partial esters of glycerol such as glycerol monostearate or glycerol Distearate is present.
- fatty alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol, fatty acids such as palmitic acid or stearic acid, liquid or solid paraffin or ozokerite, liquid to solid waxes such as such as isopropyl myristate, natural fats or some synthetic fats such as coconut fatty acid triglycerides, hydrogenated oils such as hydrogenated peanut or castor oil, or
- Suitable emulsifiers include surfactants, for example nonionic surfactants, for example polyalcohols or fatty acid esters of their ethylene oxide adducts, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters, such as sorbitan oleate or sorbitan isostearate and the like, isostearates, sterols, or polyoxyethylene fatty alcohol ethers or fatty acid esters such as anionic surfactants such as alkali metal salts of fatty alcohol sulfonates such as sodium There is lauryl sulfate, sodium cetyl sulfate or sodium stearyl sulfate, which are generally used in the presence of said fatty alcohol, for example cetyl alcohol or stearyl alcohol.
- surfactants for example nonionic surfactants, for example polyalcohols or fatty acid esters of their ethylene oxide adducts
- an agent that prevents drying of the cream for example, a polyalcohol such as glycerol, sorbitol, propylene glycol or polyethylene glycol to the water phase or to add a preservative, flavoring agent or the like to the water phase.
- a polyalcohol such as glycerol, sorbitol, propylene glycol or polyethylene glycol
- the pharmaceutical composition of the present invention may be an anhydrous ointment, suitable for topical use and containing paraffin, particularly low-viscosity paraffin, which is liquid at body temperature, or contains the above natural or partially synthetic fats, such as coconut fatty acid triglycerides.
- cerides hydrogenated oils such as hydrogenated peanut or castor oil, fatty acid partial esters of glycerol such as glycerol monostearate and distearate, silicones such as polymethylsiloxanes such as hexamethyldisiloxane or octamethyltri It may contain siloxanes, for example fatty alcohols associated with aqueous creams and which increase their capacity to absorb water, as well as sterols, wool wax, other emulsifiers and/or other additives.
- siloxanes for example fatty alcohols associated with aqueous creams and which increase their capacity to absorb water, as well as sterols, wool wax, other emulsifiers and/or other additives.
- the present invention also relates to a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; And administering to a subject a pharmaceutical composition comprising a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof and/or a compound represented by Formula 3 or a pharmaceutically acceptable salt thereof as an active ingredient.
- a pharmaceutical composition comprising a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof and/or a compound represented by Formula 3 or a pharmaceutically acceptable salt thereof as an active ingredient.
- It provides a method for improving skin elasticity or wrinkles.
- the subject includes, without limitation, mammals including humans, livestock, mice, and the like.
- the present invention relates to a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof for preparing a product for improving skin elasticity or wrinkles; and a compound represented by Formula 2 or a pharmaceutically acceptable salt thereof and/or a compound represented by Formula 3 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the term "pharmaceutical composition” may be used as a concept including the meaning of 'quasi-drug' or 'pharmaceutical'.
- composition of the present invention when used as an external skin formulation, it may additionally contain a fatty substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspension agent, a stabilizer, a foaming agent, a fragrance, and a surfactant. , water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles Or, it may contain adjuvants commonly used in the field of dermatology, such as any other ingredients commonly used in compositions for external application for skin. In addition, the components may be introduced in an amount generally used in the field of skin science.
- composition of the present invention when provided as a composition for external application, it may have an ointment, patch, gel, cream or spray formulation, but is not limited thereto.
- composition for external application of the present invention may be particularly preferably used as a parenteral preparation, and for example, the composition for external application may include a suitable pharmaceutically acceptable base such as petrolatum and stearyl alcohol; suitable pharmaceutically acceptable surfactants such as polysorbate and sorbitan sesquioleate; suitable pharmaceutically acceptable moisturizers such as glycerin; suitable pharmaceutically acceptable solvents; and a flavoring agent, a colorant, a stabilizer, a viscosifying agent, and the like can be prepared by a conventional method for preparing a composition for external application for skin.
- a suitable pharmaceutically acceptable base such as petrolatum and stearyl alcohol
- suitable pharmaceutically acceptable surfactants such as polysorbate and sorbitan sesquioleate
- suitable pharmaceutically acceptable moisturizers such as glycerin
- suitable pharmaceutically acceptable solvents suitable pharmaceutically acceptable solvents
- a flavoring agent, a colorant, a stabilizer, a viscosifying agent, and the like can be prepared by a
- composition of the present invention when the composition of the present invention is provided as a quasi-drug composition, in addition to containing at least one compound selected from the group consisting of hydroxycinnamic acid, isoamyl acetate and betaine or a pharmaceutically acceptable salt thereof as an active ingredient, Depending on the pharmaceutically acceptable carrier, excipients or diluents may be further included.
- the pharmaceutically acceptable carrier, excipient or diluent is not limited as long as the effect of the present invention is not impaired, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, aromatics, preservatives, and the like. can include
- the quasi-drug composition may be exemplified by a disinfectant cleanser, shower foam, ointment, wet tissue, coating agent, etc., and preferably may be prepared as a semi-solid preparation such as an external ointment or lotion, but is not limited thereto.
- the formulation method, dosage, usage method, components, etc. of the quasi-drug may be appropriately selected from conventional techniques known in the art.
- quadsi-drug refers to an article that exhibits effects of treatment, alleviation, treatment, or prevention of disease, but has a lesser effect on the human body than pharmaceuticals. Excluding items used for pharmaceutical purposes under the Pharmaceutical Affairs Act, including items according to the classification standards separately set by the Ministry of Health and Welfare. Specifically, it may be an external skin preparation or personal hygiene product, but is not limited thereto.
- each of the above-mentioned components included in the cosmetic composition according to the present invention is preferably within the range of not exceeding the maximum amount specified in the regulations related to "Cosmetic Use/Permission" prescribed by the government of each country, the cosmetic of the present invention may be included in the composition.
- the cosmetic of the present invention may be included in the composition.
- it may be to comply with the scope specified in the "Technical Specifications for Safety of Cosmetics" stipulated by the Chinese government.
- the present invention is a compound represented by Formula 1; And it provides a composition comprising the compound represented by Formula 2 and/or the compound represented by Formula 3 at the same time.
- the composition has a more excellent skin elasticity or wrinkle improvement effect than a composition containing the compound represented by Formula 1 alone, the compound represented by Formula 2 alone, or the compound represented by Formula 3 alone.
- 1 is a view comparing the case where the basement membrane was irradiated with UV and then treated with cordycepin and andragrapolide and the case without treatment.
- the medium for culture was a medium made by mixing DMEM (Dulbecco Modified Eagle Medium - Thermo Fisher Scientific) with 10% FBS (Fetal Bovine Serum) and 1% Antibiotics (Penicillin streptomycin). After that, 20000 cells were planted in a 6 well plate, and after 24 hours, the DMEM culture medium was treated with a sample containing each component according to Tables 1 and 2 in the contents shown in Tables 1 and 2, and cultured for another 48 hours. At this time, as a control group, DMEM medium to which no other components were added was used.
- DMEM Dulbecco Modified Eagle Medium - Thermo Fisher Scientific
- FBS Fetal Bovine Serum
- Antibiotics Penicillin streptomycin
- cDNA was synthesized by purifying intracellular RNA, and the expression level of FGF10 mRNA was analyzed using the qPCR method.
- Table 1 shows the expression level compared to the control group when cordycepin and andragrapolide were treated alone or together.
- Table 2 shows the expression level compared to the control group when cordycepin and quercetin were treated alone or together.
- adenosine is a substance well known to have a skin wrinkle improvement effect, but it has been confirmed that there is no effect of enhancing the expression of FGF 10.
- Live pig skin (used for experiments immediately after slaughter) was purchased from Apurus, and 10% FBS was added to DMEM (Dulbecco Modified Eagle Medium - Thermo Fisher Scientific) under 37°C and 5% carbon dioxide conditions in a carbon dioxide incubator. (Fetal Bovine Serum), 1% Antibiotics (Penicillin streptomycin), and 0.02% Tetracyclin were used for culture. After stabilizing the pig skin in a 6 well hanging insert (MILLIPORE) for 24 hr, UVB was irradiated at an intensity of 1 J/cm 2 using a UV irradiator to induce basement membrane destruction.
- MILLIPORE 6 well hanging insert
- UV irradiation was irradiated a total of three times by a method of resting for 2 hours after irradiation for 5 minutes.
- a sample containing 0.1% of cordycepin and 0.1% of andragrapolide was applied to the pig skin surface and treated for 48 hours.
- H&E staining was requested to TEGO science.
- DMEM was exchanged once in the morning and once in the afternoon. The results of the experiment are shown in FIG. 1 .
- the basement membrane is irradiated with UV, the basement membrane is flattened, and when cordycepin and andrographolide are treated thereon, it can be confirmed that the flattened basement membrane is restored.
- Cordycepin 0.002 quercetin 0.002 Purified water balance glycerin 8.0 Butylene Glycol 4.0 hyaluronic acid extract 5.0 beta glucan 7.0 carbomer 0.15
- Appropriate amount pigment Appropriate amount triethanolamine 0.15
- the measuring device is a device that can measure the surface image of the skin using a light emitting diode (LED light source), and extracts data from the 3D shape image of the built-in program, digitizes the skin condition, and utilizes the image.
- LED light source light emitting diode
- Skin elasticity measurement is performed using a Dermal torque meter (Dia-Stron, United Kingdom) It was measured using, and the test site (ball) was measured three times and the average value was used as evaluation data.
- the measurement principle is measured using the torsional method between a 3mm guard ring and a central disk.
- the Ur/Ue value is used as an index for evaluating elasticity in the skin, and it means that the elasticity in the skin improves as the measured value increases.
- the measurement result was calculated as follows to calculate the improvement rate, and the improvement rate is shown in Table 4 below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
시료 및 농도 | 발현량 (대조군 대비 %) |
코디세핀 8 ppm | 148 |
안드로그라폴라이드 0.2 ppm | 141 |
코디세핀 8 ppm + 안드로그라폴라이드 0.2 ppm | 536 |
아데노신 8ppm | 88 |
시료 및 농도 | 발현량 증가 (대조군 대비 %) |
코디세핀 0.2 ppm | 102 |
쿼세틴 0.2 ppm | 63 |
코디세핀 0.2 ppm + 쿼세틴 0.2ppm | 234 |
아데노신 8ppm | 88 |
아데노신 8ppm + 쿼세틴 0.2ppm | 59 |
제조예 | |
코디세핀 | 0.002 |
쿼세틴 | 0.002 |
정제수 | 잔량 |
글리세린 | 8.0 |
부틸렌글리콜 | 4.0 |
히알루론산 추출물 | 5.0 |
베타글루칸 | 7.0 |
카보머 | 0.15 |
카프릴릭/카프릭 트리글리세라이드 | 8.0 |
스쿠알란 | 5.0 |
세테아릴 글루코사이드 | 1.5 |
소르비탄 스테아레이트 | 0.4 |
세테아릴 알코올 | 2.0 |
방부제 | 적량 |
색소 | 적량 |
트리에탄올아민 | 0.15 |
평가 항목 | 개선율(%) |
주름 개선 | 10.5 |
탄력 개선 | 12.2 |
Claims (8)
- 제1항에 있어서,상기 화학식 1로 표현되는 화합물 또는 이의 생리학적으로 허용가능한 염의 함량은 전체 조성물 중 0.00001 중량% 내지 10 중량%로 포함하고,상기 화학식 2로 표현되는 화합물 또는 이의 생리학적으로 허용가능한 염 및/또는 상기 화학식 3으로 표현되는 화합물 또는 이의 생리학적으로 허용가능한 염의 함량은 전체 조성물 중 0.00001 중량% 내지 10 중량%로 포함하는 피부 탄력 또는 주름 개선용 화장료 조성물.
- 제1항에 있어서,상기 화학식 1로 표현되는 화합물 또는 이의 생리학적으로 허용가능한 염; 및 상기 화학식 2로 표현되는 화합물 또는 이의 생리학적으로 허용가능한 염 및/또는 상기 화학식 3으로 표현되는 화합물 또는 이의 생리학적으로 허용가능한 염의 100:1 내지 1:100 중량비를 포함하는 피부 탄력 또는 주름 개선용 화장료 조성물.
- 제1항에 있어서,상기 조성물은 피부 기저막 강화 효과를 가지는 것인, 피부 탄력 또는 주름 개선용 화장료 조성물.
- 제5항에 있어서,상기 화학식 1로 표현되는 화합물 또는 이의 약학적으로 허용가능한 염의 함량은 전체 조성물 중 0.00001 중량% 내지 10 중량%로 포함하고,상기 화학식 2로 표현되는 화합물 또는 이의 약학적으로 허용가능한 염 및/또는 상기 화학식 3으로 표현되는 화합물 또는 이의 약학적으로 허용가능한 염의 함량은 전체 조성물 중 0.00001 중량% 내지 10 중량%로 포함하는 피부 탄력 또는 주름 개선용 약학적 조성물.
- 제5항에 있어서,상기 화학식 1로 표현되는 화합물 또는 이의 약학적으로 허용가능한 염; 및 상기 화학식 2로 표현되는 화합물 또는 이의 약학적으로 허용가능한 염 및/또는 상기 화학식 3으로 표현되는 화합물 또는 이의 약학적으로 허용가능한 염의 100:1 내지 1:100 중량비를 포함하는 피부 탄력 또는 주름 개선용 약학적 조성물.
- 제1항에 있어서,상기 조성물은 피부 기저막 강화 효과를 가지는 것인, 피부 탄력 또는 주름 개선용 약학적 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/566,308 US20240261318A1 (en) | 2021-06-04 | 2022-06-02 | Anti-aging cosmetic composition |
CA3221157A CA3221157A1 (en) | 2021-06-04 | 2022-06-02 | Anti-aging cosmetic composition |
CN202280039995.5A CN117460491A (zh) | 2021-06-04 | 2022-06-02 | 抗老化化妆料组合物 |
JP2023574488A JP2024520678A (ja) | 2021-06-04 | 2022-06-02 | 抗老化化粧料組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0072613 | 2021-06-04 | ||
KR20210072613 | 2021-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022255810A1 true WO2022255810A1 (ko) | 2022-12-08 |
Family
ID=84324458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/007823 WO2022255810A1 (ko) | 2021-06-04 | 2022-06-02 | 항노화 화장료 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240261318A1 (ko) |
JP (1) | JP2024520678A (ko) |
KR (1) | KR20220164443A (ko) |
CN (1) | CN117460491A (ko) |
CA (1) | CA3221157A1 (ko) |
WO (1) | WO2022255810A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040161435A1 (en) * | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
KR20150116659A (ko) * | 2014-04-08 | 2015-10-16 | 바이오스펙트럼 주식회사 | 천심련추출물 또는 안드로그라폴라이드 또는 이의 염을 포함하는 피부상태 개선용 조성물 |
KR20160019769A (ko) * | 2014-08-12 | 2016-02-22 | 주식회사 엘지생활건강 | 코디세핀 또는 이의 약학적으로 허용가능한 염을 포함하는 피부 미백, 탄력, 주름개선, 보습 또는 항염증용 화장료 또는 약학 조성물 |
WO2016045902A1 (en) * | 2014-09-22 | 2016-03-31 | Unilever Plc | Anti-ageing composition comprising resveratrol and andrographolide |
KR20160126896A (ko) * | 2015-04-24 | 2016-11-02 | 농업회사법인 비센 주식회사 | 봉독 추출물을 포함하는 화장료 조성물 및 이의 제조방법 |
-
2022
- 2022-06-02 JP JP2023574488A patent/JP2024520678A/ja active Pending
- 2022-06-02 CN CN202280039995.5A patent/CN117460491A/zh active Pending
- 2022-06-02 US US18/566,308 patent/US20240261318A1/en active Pending
- 2022-06-02 CA CA3221157A patent/CA3221157A1/en active Pending
- 2022-06-02 WO PCT/KR2022/007823 patent/WO2022255810A1/ko active Application Filing
- 2022-06-03 KR KR1020220068159A patent/KR20220164443A/ko not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040161435A1 (en) * | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
KR20150116659A (ko) * | 2014-04-08 | 2015-10-16 | 바이오스펙트럼 주식회사 | 천심련추출물 또는 안드로그라폴라이드 또는 이의 염을 포함하는 피부상태 개선용 조성물 |
KR20160019769A (ko) * | 2014-08-12 | 2016-02-22 | 주식회사 엘지생활건강 | 코디세핀 또는 이의 약학적으로 허용가능한 염을 포함하는 피부 미백, 탄력, 주름개선, 보습 또는 항염증용 화장료 또는 약학 조성물 |
WO2016045902A1 (en) * | 2014-09-22 | 2016-03-31 | Unilever Plc | Anti-ageing composition comprising resveratrol and andrographolide |
KR20160126896A (ko) * | 2015-04-24 | 2016-11-02 | 농업회사법인 비센 주식회사 | 봉독 추출물을 포함하는 화장료 조성물 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
US20240261318A1 (en) | 2024-08-08 |
JP2024520678A (ja) | 2024-05-24 |
CN117460491A (zh) | 2024-01-26 |
CA3221157A1 (en) | 2022-12-08 |
KR20220164443A (ko) | 2022-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2423409T3 (es) | Nuevos derivados C-glicósidos y utilización | |
WO2013027984A2 (ko) | 녹차 성분을 함유하는 화장료 조성물 | |
KR101339096B1 (ko) | 과색소침착 피부용 피부 미백 조성물 | |
WO2011122840A2 (ko) | 멜라닌 색소 생성 억제제 및 이를 함유하는 화장료 조성물 | |
WO2017217695A1 (ko) | 알파-망고스틴, 베타-망고스틴, 감마-망고스틴 또는 가르탄닌 화합물을 유효성분으로 함유하는 피부 주름 개선 또는 피부 보습용 조성물 | |
JP4067073B2 (ja) | 皮膚化粧料 | |
KR20140055155A (ko) | 자외선 등 피부 유해물질로부터 피부를 보호하여 피부 염증 또는 노화를 개선하는 물질 살리드로사이드 | |
WO2012173382A2 (ko) | 탄시논ⅱa를 유효성분으로 함유하는 피부 외용제 조성물 | |
WO2020091295A1 (ko) | 저근백피 추출물을 유효성분으로 함유하는 여드름성 피부 개선용 또는 피지 분비 억제용 조성물 | |
WO2022255810A1 (ko) | 항노화 화장료 조성물 | |
AU2009256524B2 (en) | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid | |
KR101261731B1 (ko) | 콜라겐 생성 촉진용 피부 외용제 조성물 | |
WO2019031655A1 (ko) | 티몰을 유효성분으로 함유하는 피부 주름 또는 아토피성 피부염의 예방 또는 치료용 조성물 | |
WO2021075929A1 (ko) | 애엽 추출물을 포함하는 피부 손상 개선용 조성물 | |
WO2021241780A1 (ko) | 흰머리 억제용 조성물 및 이의 용도 | |
KR20140079571A (ko) | 얌빈 추출물을 이용한 피부 외용제 조성물 | |
KR102074859B1 (ko) | 풀루란-레티노이드 접합체를 유효성분으로 포함하는 피부노화 방지용 조성물 | |
KR101190815B1 (ko) | 세로토닌을 유효성분으로 포함하는 백반증 치료용 조성물 | |
JP3604554B2 (ja) | テルフェニル誘導体及び用途 | |
WO2018004171A1 (ko) | 지방세포 분화 촉진용 조성물 및 지방세포 분화 촉진 물질의 스크리닝 방법 | |
WO2009116838A9 (ko) | 비타민 u를 유효성분으로 함유하는 상처치유 및 피부 주름개선용 화장료 조성물 | |
KR102204367B1 (ko) | 피부 주름 개선용 화장료 조성물 | |
KR102430512B1 (ko) | 릴린 및/또는 vegf-c의 생산 및/또는 활성 촉진제 및 이를 이용한 피부 외용제 | |
KR101454515B1 (ko) | 베라트릭 산 또는 이의 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 피부상태 개선용 조성물 | |
WO2009082185A1 (ko) | 플라티코딘-디를 함유하는 피부미백제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22816469 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18566308 Country of ref document: US Ref document number: 2023574488 Country of ref document: JP Ref document number: 3221157 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280039995.5 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 28/03/2024) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22816469 Country of ref document: EP Kind code of ref document: A1 |